Lumexa Imaging Holdings, Inc. (LMRI): Entry into a Material Definitive Agreement
Lumexa Imaging Holdings, Inc. (LMRI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 d155301dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 Execution Version AMENDMENT NO. 7 AMENDMENT NO. 7, dated as of June 30, 2026 (this “ Amendment ”), by and among LUMEXA IMAGING, INC., a Delaware corporation (the “ LII Borrower ”), LUMEXA IMAGING OUTPATIENT, INC., a Delawar
How this was made
The 30-second read
Why it matters
The amendment creates a new class of replacement term loans ($822,937,500) to repay prior replacement term loans and includes a requested consent to reduce the interest rate on revolving loans.
Market read
This is a capital-structure event: refinancing size and revolver rate reduction can change financing-cost expectations and near-term credit risk perception.
What to watch
Traders should check for covenant changes, maturity profile shifts, and any incremental fees/conditions tied to the replacement term loans and revolver rate reduction—none are quantified in the excerpt.
Background
The 8-K reports entry into a material definitive agreement via Amendment No. 7 to an existing credit agreement originally dated Dec. 15, 2020 and repeatedly amended through March 30, 2026.
Ticker impact
Lumexa Imaging Holdings entered Amendment No. 7 to its credit agreement, refinancing term loans with $822.9375M replacement loans and revolver rate reduction.
Likely modest, with focus on debt-cost optics rather than a fundamental earnings reset.
The filing is a primary-source credit agreement amendment with sizable refinancing ($822.9M) and revolver rate changes, but no explicit equity-impact metrics (e.g., guidance, covenants, or cash proceeds beyond refinancing).
Market effects
Credit-market conditions and refinancing terms for healthcare imaging/lending structures may influence perceived leverage risk across similarly capitalized medtech/healthcare services issuers.
Primarily US credit/financing sentiment; limited direct regional read-through beyond lenders’ risk appetite.
Barclays and other global banks’ participation signals continued international bank appetite for this borrower’s credit risk, but impact is localized to the issuer’s capital structure.
Counterpoint
Refinancing may not materially improve equity value if it extends maturities without reducing total leverage or if fees/terms offset rate benefits.
Key entities
- issuerLumexa Imaging Holdings, Inc.
Subject of the SEC 8-K; borrower/holding entities are party to Amendment No. 7 under the credit agreement.
- lender_agentBarclays Bank PLC
Administrative agent and lead arranger for the amendment.
